WallStSmart

Boston Scientific Corp (BSX)vsEstablishment Labs Holdings Inc (ESTA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 9410% more annual revenue ($20.07B vs $211.08M). BSX leads profitability with a 14.4% profit margin vs -24.2%. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

ESTA

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 5.0Quality: 5.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Intrinsic value data unavailable for ESTA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

ESTA1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
45.2%10/10

Revenue surging 45.2% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

ESTA4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.75B3/10

Smaller company, higher risk/reward

Price/BookValuation
74.5x2/10

Trading at 74.5x book value

Return on EquityProfitability
-133.3%2/10

ROE of -133.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : ESTA

The strongest argument for ESTA centers on Revenue Growth. Revenue growth of 45.2% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : ESTA

The primary concerns for ESTA are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 15.96 is elevated, increasing financial risk.

Key Dynamics to Monitor

BSX profiles as a growth stock while ESTA is a hypergrowth play — different risk/reward profiles.

ESTA carries more volatility with a beta of 0.96 — expect wider price swings.

ESTA is growing revenue faster at 45.2% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 28/100) and 15.9% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Establishment Labs Holdings Inc

HEALTHCARE · MEDICAL DEVICES · USA

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for cosmetic and reconstructive plastic surgery. The company is headquartered in Alajuela, Costa Rica.

Visit Website →

Want to dig deeper into these stocks?